Case study: Neuropsychiatric symptoms associated with the antimalarial agent mefloquine

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 36, Issue 11, 1997, Pages 1606-1608

  Clattenburg, Richard N ^a   Donnelly, Craig L ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Antimalarial; Anxiety; Child; Mefloquine (Lariam )

Indexed keywords

MEFLOQUINE;

ARTICLE; CASE REPORT; COGNITIVE THERAPY; HUMAN; MALARIA; MALE; MENTAL DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SCHOOL CHILD; TRAVEL;

EID: 0030773785     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0890-8567(09)66572-2     Document Type: Article

References (5)

1. Barrett P, Emmins P, Clarke PD, Bradley DJ (1996), Comparison of the adverse events associated with the use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 313:525-528
2. Dyer C (1996), Legal aid won for malarial drug case. BMJ 313:643
3. Lobel HO, Miani M, Eng T, Bernard K, Hightower A, Campbell C (1993), Long-term malaria prophylaxis with weekly mefloquine. Lancet 341:848-851
4. Medical Economics Data (1996), Physicians' Desk Reference, 50th ed. Oradell, NJ: Medical Economics Data, p 2128
5. Steffen R, Fuchs E, Schildknecht J et al. (1993), Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 341:1299-1303